



Artificial Intelligence in Diabetes Prediction: Transforming Early Diagnosis and Risk Assessment

Dr. Farah Khan *

Dept. of Digital Health Sciences, Global Tech Medical University, UAE

***Corresponding author:** Dr. Farah Khan, Dept. of Digital Health Sciences, Global Tech Medical University, UAE, Email: f.khan@gtmu.ac.ae

Citation: Samuel J (2025) Artificial Intelligence in Diabetes Prediction: Transforming Early Diagnosis and Risk Assessment. Endocrinol Diabetes Res 11:447

Received: 01-Oct-2025, Manuscript No. ecdr-26-182694; **Editor assigned:** 4-Oct-2025, Pre-QC No. ecdr-26-182694 (PQ); **Reviewed:** 19-Oct-2025, ecdr-26-182694; **Revised:** 25-Oct-2025, Manuscript No. ecdr-26-182694 (R); **Published:** 31-Oct-2025, DOI: 10.4172/2324-8777.1000447

Introduction

Diabetes mellitus is a global health challenge, with type 2 diabetes accounting for the majority of cases. Early detection and intervention are critical for preventing complications such as cardiovascular disease, nephropathy, and neuropathy. Traditional risk assessment relies on clinical factors, laboratory tests, and lifestyle evaluation, which may not fully capture the complexity of individual risk. Artificial intelligence (AI), encompassing machine learning (ML) and deep learning algorithms, has emerged as a powerful tool for predicting diabetes by analyzing complex datasets, identifying patterns, and providing personalized risk assessments [1,2].

Discussion

AI-based diabetes prediction leverages large volumes of clinical, biochemical, genetic, and lifestyle data to identify individuals at risk. Machine learning algorithms such as support vector machines, decision trees, and random forests have been applied to datasets including age, body mass index, blood pressure, fasting glucose, lipid profiles, and family history. These models can uncover nonlinear relationships between variables that traditional statistical methods may overlook, improving predictive accuracy [3,4].

Deep learning, a subset of AI, utilizes neural networks to process high-dimensional and heterogeneous data. Deep learning models can integrate electronic health records, continuous glucose monitoring data, and even wearable sensor outputs to predict the onset of diabetes and identify patterns of glycemic variability. For example, AI algorithms can detect subtle trends in blood glucose fluctuations, activity levels, and dietary habits to provide individualized risk scores [5].

AI also enables population-level risk stratification. Predictive models can identify high-risk groups in large datasets, allowing targeted interventions, lifestyle modification programs, and early pharmacologic therapy. Additionally, AI systems can be used to

predict progression from prediabetes to overt diabetes, facilitating timely monitoring and prevention strategies. Integration with mobile health platforms and wearable devices enhances real-time monitoring and continuous risk assessment.

Despite its promise, AI in diabetes prediction faces challenges. Model accuracy depends on the quality and diversity of input data, and biases in training datasets can reduce generalizability. Data privacy and security concerns are also critical, especially when using personal health information. Clinical adoption requires validation in diverse populations and clear interpretability of AI-generated predictions to guide healthcare decisions.

Conclusion

Artificial intelligence offers a transformative approach to diabetes prediction by leveraging complex data to deliver early, personalized risk assessments. Machine learning and deep learning algorithms enhance the accuracy of identifying individuals at risk and predicting disease progression, enabling timely intervention and prevention strategies. Continued research, robust validation, and integration into clinical practice are essential to maximize the potential of AI, ultimately improving outcomes and reducing the burden of diabetes globally.

References

1. Selvaraj C, Chandra I, Singh SK (2021) Artificial intelligence and machine learning approaches for drug design: challenges and opportunities for the pharmaceutical industries. *Molecular diversity* 1-21.
2. Henstock P (2021) Artificial intelligence in pharma: positive trends but more investment needed to drive a transformation. *Archives of Pharmacology and Therapeutics* 2: 24-28.
3. Mak KK, Pichika MR (2019) Artificial intelligence in drug development: present status and prospects. *Drug Discovery Today* 24: 773-780.
4. Bhattamisra SK, Banerjee P, Gupta P, Mayuren J, Patra S, et al. (2023) Artificial intelligence in pharmaceutical and healthcare research. *Big Data and Cognitive Computing* 7: 10.
5. Patil P, Nrip NK, Hajare A, Hajare D, Patil MK, et al. (2023) Artificial intelligence and tools in pharmaceuticals: An overview. *Research Journal of Pharmacy and Technology* 16: 2075-2082.